ΑρΑ«ΚΣΖ΅

Meeting Coverage

ASCO Future Focus: Immunotherapy

Future Focus from the American Society of Clinical Oncology

'Very Clear Signal' That Survival Improved With Addition of Durvalumab in SCLC

Next steps include understanding which patients get the most benefit

image

Latest ASCO Future Focus: Immunotherapy Meeting Coverage

Advances in Immunotherapy for Prostate Cancer: Key Findings From ASCO 2024

Tanya Dorff, MD, reviews two prostate cancer immunotherapy studies

July 1, 2024
Highlights on Immunotherapy for Melanoma From ASCO 2024

Ahmad Tarhini, MD, PhD, discusses some of the exciting data presented at the meeting

June 24, 2024
Does Immunotherapy Lower Risk of Secondary Cancers?

Retrospective analysis of Cleveland Clinic data looks to answer the question

June 18, 2024
FAK Inhibitor Boosts Anti-PD1 Immunotherapy in Pancreatic Cancer

Jun Gong, MD, says the future is bright for immunotherapy-based combinations

July 14, 2023
Can a Simple Beta-Blocker Improve Immunotherapy Responses?

A phase II trial examined propranolol's effect on adrenergic stress in esophageal cancer patients

July 7, 2023
Adopting Immunotherapy in MSI-High/dMMR Colorectal Cancers

Van Karlyle Morris, MD, discusses the success of checkpoint blockade in this population

June 30, 2023
Immunotherapy in Lung Cancer: Current Landscape and Future Directions

"There's going to be more immunotherapy trials coming," says Jorge Nieva, MD

June 23, 2023

Latest Oncology/Hematology Meeting Coverage